



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Patent Examining Operations

Application of : Mark E. Samuels et al.
Serial No. : 10/552,158 Art Unit: 1656
Filed : 11 December 2006 Examiner: Monshipouri, M.
For : Juvenile Hemochromatosis Gene (HFE2A), Expression
Products and Uses Thereof
Docket No. : 760050-154

17 August 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO RESTRICTION

Sir:

In response to the Restriction Requirement, mailed 22 June 2009, Applicants elect the invention of Group II (claims 33-43 and 91-97), drawn to a method of treating a disorder utilizing modulators of the HFE2A gene or its product. In addition, Applicants elect the sequence of SEQ ID NO: 12 with traverse. Applicants also elect as a disease anemia of inflammation. Applicants also elect as the modulator an anti-sense molecule.

Prior to examination of the above-referenced patent application on the merits, Applicant requests that the application be amended as follows: